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Abstract
Background: Severe hypertriglyceridaemia (HTG) is uncommon but most prevalent in subjects
with type 2 diabetes mellitus (T2DM) and excess ethanol intake.
Case presentation: We describe a case of a middle age male (53 y) presenting to the emergency
room with acute atypical central chest pain and severe HTG in the absence of evidence of overt
ischaemic heart disease (IHD). Admission ECG and EET (exercise tolerance test) were negative for
reversible ischaemic changes. His admission glucose was 12.2 mmol/l, triglycerides (TG) were 103
mmol/l, total cholesterol 37 mmol/l. Cardiac Troponin T could not be measured on three
occasions but CK MB mass was normal at 3 µg/l. The patient was started on Bezafibrate 400 mg
OD, Simvastatin 20 mg nocte, Omacor (Omega-3 fish oil) 1 gm bd and Metformin 500 mg tds. Four
weeks after admission, lipid and liver profiles showed remarkable improvement, TG 2.9 mmol/l,
Tchol 6.3 mmol/l and HDLc 1.5 mmol/l, ALAT and GGT were normal.
Conclusion: A case report of severe hypertriglyceridaemia with atypical presentation
demonstrate the role of combined lipid modifying agents in lowering triglycerides and cholesterol
as well as improving liver enzymes.
Background
Severe hypertriglyceridemia (HTG) is an uncommon met-
abolic disorder. Prevalence of severe HTG, defined as trig-
lycerides (TG) greater than 22 mmol/l, is estimated to be
1.8 cases per 10,000 adult Caucasians [1]. It is exacerbated
by uncontrolled diabetes mellitus, obesity, excess ethanol
intake and sedentary habits, all of which are more preva-
lent in industrialized societies than in developing nations.
TG are synthesized in the liver and intestine and packaged
into lipoproteins. Chylomicron is synthesized in the
intestine, and very-low-density-lipoprotein (VLDL) is syn-
thesized in the liver. Chylomicron and VLDL normally
undergo rapid metabolism via the action of lipoprotein
lipase (LPL), hepatic lipase (HL), and cholesterol ester
transfer protein (CETP). During catabolism, any distur-
bance that causes increased synthesis of chylomicron and/
or VLDL or decreased metabolic breakdown will cause ele-
vations in TG levels [1]. That disturbance may be as com-
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mutation of an enzyme in the lipid metabolism pathway.
Two rare genetic causes of severe HTG are LPL deficiency
and apolipoprotein (apo) C-II deficiency lead to TG eleva-
tions that are astonishingly high. A common genetic form
called familial combined hyperlipidaemia (FCHL) charac-
terised by multiple lipoprotein phenotypes and strongly
associated with premature cardiovascular disease. The
prevalence of FCHL is 1/500 in adult caucasians, the
genetic of FCHL is not yet clearly defined [2]. The com-
monest presentations of severe HTG are recurrent epi-
sodes of severe abdominal pain (acute pancreatitis) and
eruptive xanthomata (which occur when TG-rich lipopro-
teins are taken up by skin macrophages in discrete loca-
tions usually involving the back and proximal
extremities) to the dermatologists.
Case presentation
Here we describe a case of 53-year-old white male admit-
ted to the emergency room with acute atypical central
chest pain of 8 hours duration. The chest pain was mainly
at rest; was non-radiating and was not associated with
sweating, palpitation, nausea or vomiting. He reported
three similar episodes during the previous week. He
denied any alteration in his bowel habits or other gastro-
intestinal symptoms. His only medical problem was
hypertension that was diagnosed 6 months ago and he
was commenced on Bendrofluazide but he admitted
being non-complaint with his medication. He smoked 20
cigarettes/day and drank 6–8 units/day. His father and
five of his paternal uncles died from IHD in their early fif-
ties. His mother died at the age of 57 from carcinoma of
the cervix and he has one living sister. He walked up to 5
miles a day without any chest discomfort prior to this
admission.
On examination, he was tachycardiac at 103 b/min but in
sinus rhythm, blood pressure 167/129 mmHg, oxygen
saturation 97% at room air, respiratory rate 20/min and
temperature was normal at 36.7°C. BMI was 27.6. Cardi-
ovascular, respiratory and abdominal examinations were
unremarkable. Fundoscopic examination revealed lipae-
mia retinalis. A 12 lead admission ECG was negative for
ischaemic changes apart for peaked T waves. Chest X-ray
did not revealed any abnormality. Troponin T could not
be measured on three occasions due to lipaemia (hyper-
triglyceridaemia) but CK-MB was normal 3 µg/l. Exercise
tolerance test on the next morning was negative for any
reversible ischaemic changes. Admission lipid profile
revealed a markedly raised TG at 103 mmol/l. Next morn-
ing repeats lipid profile; TG and total cholesterol (Tchol)
were 57 mmol/l and 32 mmol/l, respectively. HDL choles-
terol was unmeasurable with urea 4.5 mmol/l, creatinine
86 µmol/l, total protein 67 g/l, albumin 39 g/l and urine
albumin/creatinine ratio 9.7. Fasting glucose and HBA1c
were normal at 4.5 mmol/l and 5.8%, respectively. Liver
function test revealed a moderately raised ALT and GGT at
60 U/l and 730 U/l, respectively. Serum amylase was nor-
mal at 51 U/l.
The Initial impression was a case of acute coronary syn-
drome and familial combined hyperlipidaemia. The
patient was commenced on anti-angina medications,
glycerine trinitrate (GTN) and β-blocker (Bisprolol) and
for his hyperlipidaemia he was commenced on Bezafiba-
rate 400 mg od. Five days post admission the pain
improved to a great extent other than mild discomfort and
a repeat lipid profile revealed a TG 13.7 mmol/l and Tchol
15.3 mmol/l. For that he was commenced on Simvastatin
20 mg nocte, Omacor 1 gm bd, and Metformin 500 mg
tds in addition to the Bezafibrate. An urgent dietary review
was arranged, with advice to reduce his fat intake to <10%
of total calories intake. Two weeks after admission, lipid
profile improved with TG and Tchol at 5.0 mmol/l and
8.3 mmol/l, respectively, HDL cholesterol was at 1.5
mmol/l. Four weeks from the acute presentation, he was
reviewed in the lipid clinic with TG 2.9 mmol/l, Tchol 6.3
mmol/l and HDL cholesterol at 1.4 mmol/l. Liver profile
improved with normal ALT at 30 U/l and mildly raised
GGT at 60 U/l. Apolipoprotein E genotyping was apoE3/
E4. The patient's chest pain and exercise tolerance
improved to a great extent (he started regular exercise and
he cutdown his ethanol intake to 2 units/day and smok-
ing to 2–3 cigarettes/day). The cardiac team has reviewed
the patient, his anti-angina medication was discontinued
and he was discharged from the cardiac clinic.
This is a middle age male with most probably FCHL exac-
erbated by excess ethanol intake, being over-weight and
insulin resistant. FCHL is caused by hepatic over-produc-
tion of VLDL, either with or without impaired clearance of
TG-rich lipoproteins from plasma. In this group of
patients there is a compromise of chylomicron clearance,
perhaps due to competition for the same common path-
way of lipid hydrolysis in the vascular compartment [2].
The diagnosis of FCHL in this patient is based on presence
of moderately to markedly raised Tchol. The familial
nature of our patient hyperlipidaemia is illustrated by the
fact that his father and five of his paternal uncles have
died from IHD in their early fifties. Despite the fact that
our patient did not reveal any evidence of ischaemic
changes on ECG and ETT, nonetheless, these tools do not
exclude occult coronary atherosclerosis. Besides subjects
with FCHL are at high risk of future IHD [2]. The possibil-
ity of acute pancreatitis has been rule out based on clinical
presentation; normal C.T abdomen and serum amylase
and improved pain pattern few days post admission.
Our patient presentation provides examples of the various
features of severe HTG, which included milky appearancePage 2 of 4
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the veins and bright-red colour of the arteries blend into a
pink colour, making each difficult to distinguish, a condi-
tion called lipaemia retinalis. In addition, our patient pre-
sented with atypical chest pain in the absence of
ischaemic changes on ECG and ETT. It is thought that the
aggregation of VLLD and chylomicron can obstruct the
capillary bed, resulting in tissue ischaemia [1]. Reviewing
the literature, we were able to find two case reports of
severe HTG presenting with acute chest pain in the
absence of evidence of IHD, one patient was known to
have T2DM and the other patient was a pregnant lady
[3,4]. The relationship between TG and cardiovascular is
less clear compared to cholesterol. However, there are a
number of postulated mechanisms that have linked raised
TG with IHD. These include retention of chylomicron and
VLDL remnants, small dense LDL, low HDL and increased
coagulability of the plasma [1]. There have been multiple
conflicting studies regarding the role of triglycerides and
the development of IHD. HTG is clearly associated with
IHD in univariate analysis [1]. However, many multivari-
ate studies have shown that its risk is markedly attenuated
after adjustment for other IHD risk factors, namely low
HDL and increased small, dense LDL particles. A recent
review of the literature concluded that treating isolated
HTG does not prevent coronary events [5]. On the other
hand; there have been many other studies that have
shown HTG to be an independent risk factor for IHD even
after adjustment for HDL and LDL [6-8].
Despite the controversy that exist between hypertriglycer-
idaemia and IHD, severe hypertriglyceridaemia is well
established cause of pancreatitis, therefore, it is imperative
to manage subjects with severe hypertriglyceridaemia in
order to avoid pancreatic damage [9].
Our patient was commenced on a Fibrate which is a spe-
cific transcription factors belonging to the nuclear hor-
mone receptor superfamily, termed peroxisome
proliferator-activated receptors (PPARs). Fibrates work by
lowering hepatic apoC-III production and increasing lipo-
protein lipase that will results in a decrease in VLDL pro-
duction [10]. Our patient's TG improved over a period of
five days, nonetheless, there was reversed increase in the
ratio of Tchol to TG. Fibrates are known to be associated
with paradoxical increase in LDL cholesterol in certain
types of hyperlipidaemia especially type IV hyperlipidae-
mia [10]. For that the patient was commenced on Simvas-
tatin (3-Hydroxy-3 methylglutaryl CoA reductase
inhibitors) and Metformin (N1,N1-dimethylbiguanide),
and Omacor (Omega-3 fatty acids). Combinations of
lipid modifying agents have resulted in significant
improvement in the TG. At this stage the patient was
advised to continue on the current medications due to the
strong family history of IHD and protection against pan-
creatic damage that could predispose him to diabetes.
Moreover, the patient was adviced about the importance
of lifestyle changes, weight reduction, ethanol and smok-
ing cessation. The remarkable improvement in the triglyc-
erides level over the proceeding days post admission has
precludes the need for a more invasive approach in man-
aging this patient severe hypertriglyceridaemia by plas-
mapheresis.
This case report illustrates the importance of lipid lower-
ing agents on clearing fat deposit (steatosis) from the
liver. Despite the fact that more than two lipid-lowering
agents which some time can cause liver dysfunction were
used. There were well tolerated by the patient, and there
was a paradoxical improvement in his liver enzymes, both
ALT and GGT being normalised within the reference range
over a period of four weeks. Therefore, an understanding
of the pathogenesis and natural history of this metabolic
condition will help to identify the subset of patients with
fatty liver that could benefit from medical therapy, despite
the associated risk of hepat-toxicity with Statin and
Fibrates. Small studies on the use of Metformin and Thia-
zolidinediones (insulin sensitizers) and Fibrates in ani-
mal models and in subjects with T2DM with fatty liver
have also resulted in normalization of ALT.
In some of these studies Metformin and Fibrates reversed
hepatomegaly and steatosis on liver biopsy. [11]. The
patient was recently reviewed in the lipid clinic, his gen-
eral well-being and exercise threshold have improved to a
great extent, the pain almost disappear completely with
very un-occasional chest discomfort, the cardiac team
have discharged the patient from the cardiac clinic based
on two ETTs.
Conclusion
This is an interesting report of severe hypertriglyceridae-
mia with an atypical presentation, which demonstrates
the role of combined lipid modifying agents in lowering
triglycerides and cholesterol as well as reciprocal improve-
ments in liver enzymes.
Method: Plasma triglycerides, total cholesterol, ALT, GGT,
glucose, creatinine, urea, sodium, potassium and total
ALP were measured using the standard methods on Roche
Modular analysers (Lewis. UK).
HDL cholesterol measured using PEG-modified enzymes
and dextran sulphate. Within and between batch preci-
sion at 1.0 mmol/l were 0.9% CV (Human serum) and
1.85% CV (Human serum), respectively.
HBA1c was measured using high performance liquid
Chromatography (HPLC). Within and between batch pre-Page 3 of 4
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cision at 4.54%, 7.22% and 12.87% were 1.1, 1.3, and
1.0, and 1.1, 1, and 0.5, respectively.
Apolipoprotein E (apoE) was measured using polymerase
chain reaction (PCR).
BMI was calculated as weight (kg) divided by height (m2)
and used as an index of adiposity.
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